Vascular system-peripheral veins, percutaneous approach

85816300 Category Share

Vascular system-peripheral veins, percutaneous approach is an EFRIS commodity class (code 85816300) under Administrative interventions or procedures, physiological systems and anatomical regions, introduction and irrigation and circulatory in Uganda Revenue Authority's e-invoicing system.

31 items in this category

• 85816310Introduction of analgesics, hypnotics, sedatives into peripheral vein, percutaneous approach
  Exempt
• 85816320Introduction of anti-inflammatory into peripheral vein, percutaneous approach
  Exempt
• 85816308Introduction of antiarrhythmic into peripheral vein, percutaneous approach
  Exempt
• 85816306Introduction of autologous pancreatic islet cells into peripheral vein, percutaneous approach
  Exempt
• 85816314Introduction of blood brain barrier disruption substance into peripheral vein, percutaneous approach
  Exempt
• 85816324Introduction of clofarabine into peripheral vein, percutaneous approach
  Exempt
• 85816307Introduction of destructive agent into peripheral vein, percutaneous approach
  Exempt
• 85816317Introduction of electrolytic and water balance substance into peripheral vein, percutaneous approach
  Exempt
• 85816313Introduction of glucarpidase into peripheral vein, percutaneous approach
  Exempt
• 85816328Introduction of high-dose interleukin-2 into peripheral vein, percutaneous approach
  Exempt
• 85816303Introduction of human b-type natriuretic peptide into peripheral vein, percutaneous approach
  Exempt
• 85816330Introduction of immunostimulator into peripheral vein, percutaneous approach
  Exempt
• 85816329Introduction of immunosuppressive into peripheral vein, percutaneous approach
  Exempt
• 85816304Introduction of insulin into peripheral vein, percutaneous approach
  Exempt
• 85816316Introduction of intracirculatory anesthetic into peripheral vein, percutaneous approach
  Exempt
• 85816327Introduction of low-dose interleukin-2 into peripheral vein, percutaneous approach
  Exempt
• 85816325Introduction of monoclonal antibody into peripheral vein, percutaneous approach
  Exempt
• 85816305Introduction of nonautologous pancreatic islet cells into peripheral vein, percutaneous approach
  Exempt
• 85816318Introduction of nutritional substance into peripheral vein, percutaneous approach
  Exempt
• 85816321Introduction of other anti-infective into peripheral vein, percutaneous approach
  Exempt
• 85816326Introduction of other antineoplastic into peripheral vein, percutaneous approach
  Exempt
• 85816311Introduction of other diagnostic substance into peripheral vein, percutaneous approach
  Exempt
• 85816302Introduction of other hormone into peripheral vein, percutaneous approach
  Exempt
• 85816315Introduction of other therapeutic substance into peripheral vein, percutaneous approach
  Exempt
• 85816323Introduction of other thrombolytic into peripheral vein, percutaneous approach
  Exempt
• 85816322Introduction of oxazolidinones into peripheral vein, percutaneous approach
  Exempt
• 85816309Introduction of platelet inhibitor into peripheral vein, percutaneous approach
  Exempt
• 85816312Introduction of radioactive substance into peripheral vein, percutaneous approach
  Exempt
• 85816331Introduction of recombinant human-activated protein c into peripheral vein, percutaneous approach
  Exempt
• 85816319Introduction of serum, toxoid and vaccine into peripheral vein, percutaneous approach
  Exempt
• 85816301Introduction of vasopressor into peripheral vein, percutaneous approach
  Exempt